MDT

86.75

-0.41%↓

115.21

+0.1%↑

VEEV

156.87

+3.57%↑

HQY

78.33

+0.27%↑

TLRY

6.47

-1.67%↓

MDT

86.75

-0.41%↓

115.21

+0.1%↑

VEEV

156.87

+3.57%↑

HQY

78.33

+0.27%↑

TLRY

6.47

-1.67%↓

MDT

86.75

-0.41%↓

115.21

+0.1%↑

VEEV

156.87

+3.57%↑

HQY

78.33

+0.27%↑

TLRY

6.47

-1.67%↓

MDT

86.75

-0.41%↓

115.21

+0.1%↑

VEEV

156.87

+3.57%↑

HQY

78.33

+0.27%↑

TLRY

6.47

-1.67%↓

MDT

86.75

-0.41%↓

115.21

+0.1%↑

VEEV

156.87

+3.57%↑

HQY

78.33

+0.27%↑

TLRY

6.47

-1.67%↓

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Avatud

SektorTervishoid

0.38 -7.32

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.38

Max

0.4

Põhinäitajad
By Trading Economics
Sissetulek	983K -47M
Müük	505K 14M
Kasumimarginaal	-342.329
Töötajad	161
EBITDA	-346K -46M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+973.17% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-24M 81M
Eelmine avamishind	7.7
Eelmine sulgemishind	0.38

Uudiste sentiment

By Acuity

76%

24%

321 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. apr 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

12. apr 2026, 23:38 UTC

Market Talk

Uudisväärsed sündmused

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

12. apr 2026, 23:38 UTC

Market Talk

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

12. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

12. apr 2026, 23:31 UTC

Market Talk

A2 Milk's Supply Issues Likely Temporary -- Market Talk

12. apr 2026, 23:09 UTC

Market Talk

Uudisväärsed sündmused

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

12. apr 2026, 23:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. apr 2026, 23:06 UTC

Market Talk

Australian Dollar Ripe for a Downward Correction -- Market Talk

12. apr 2026, 22:56 UTC

Uudisväärsed sündmused

Spot Gold Falls 1.9% to $4,658.65 per Ounce

12. apr 2026, 22:54 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

12. apr 2026, 22:53 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

12. apr 2026, 22:51 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

12. apr 2026, 22:50 UTC

Market Talk

Uudisväärsed sündmused

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

12. apr 2026, 22:37 UTC

Market Talk

Uudisväärsed sündmused

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

11. apr 2026, 08:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

11. apr 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

11. apr 2026, 08:20 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

11. apr 2026, 00:00 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Big Yachts, Big Bucks -- Barrons.com

10. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10. apr 2026, 21:01 UTC

Tulu

Cango Inc.: Files Annual Report on Form 20-F With SEC

10. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10. apr 2026, 20:10 UTC

Omandamised, ülevõtmised, äriostud

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. apr 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10. apr 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10. apr 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. apr 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10. apr 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

973.17% tõus

12 kuu keskmine prognoos

Keskmine 4.4 USD 973.17%

Kõrge 15 USD

Madal 0.3 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

321 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.